Global Hematologic Malignancies Testing Market Analysis (2026–2030): Strategic Insights
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Hematologic Malignancies Testing Market Projected To Reach By 2030?
The size of the hematologic malignancies testing market has experienced rapid growth in recent years. This market is projected to expand from $3.58 billion in 2025 to $4.06 billion in 2026, at a compound annual growth rate (CAGR) of 13.4%. Historically, the expansion observed in this market can be attributed to several factors including the increasing prevalence of hematologic cancers, the broader integration of molecular diagnostics, the enlargement of diagnostic laboratory networks, a rise in the utilization of CBC and flow cytometry, and enhanced access to oncology testing services.
The market size for testing of hematologic malignancies is anticipated to experience significant expansion over the coming years. It is projected to reach $6.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.2%. This growth during the projected timeframe is largely driven by factors such as a heightened demand for precision oncology diagnostics, an expanding incorporation of AI-based data interpretation, the broadening of companion diagnostics, an increased uptake of MRD monitoring, and greater investments in sophisticated diagnostic technologies. Key trends anticipated during the forecast period encompass a wider embrace of NGS-based diagnostic testing, a growing reliance on flow cytometry for MRD detection, an increasing convergence of molecular and genetic assays, the progression of personalized diagnostic profiling, and a sharpened emphasis on timely and precise subtyping.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Drivers Are Fueling The Growth Of The Hematologic Malignancies Testing Market?
The increasing frequency of cancer diagnoses is projected to fuel the expansion of the hematologic malignancies testing market moving ahead. A cancer diagnosis involves determining the existence, kind, and progression of cancer in an individual through diverse medical assessments like imaging, lab analyses, and biopsies. This surge in diagnoses stems from enhanced availability of screening initiatives and greater public understanding, leading to earlier detection. Hematologic malignancies testing supports cancer diagnoses by facilitating prompt discovery, precise categorization, and ongoing surveillance of blood cancers, thus directing specific treatment strategies and enhancing patient results. For example, the American Cancer Society, an US-based nonprofit organization, reported that more than 2 million new cancer cases are identified in the US in 2024, marking a 4% rise from prior years. Consequently, the growing count of cancer diagnoses propels the growth within the hematologic malignancies testing market.
How Is The Hematologic Malignancies Testing Market Broken Down By Segment Categories?
The hematologic malignancies testing market covered in this report is segmented –
1) By Test Type: Complete Blood Count (CBC), Flow Cytometry, Molecular Testing, Genetic Testing, Others Test Type
2) By Product: Kits, Services
3) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohisto Chemistry (IHC), Cytogenetics, Others Technology
4) By Therapeutic Indication: Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others Therapeutic Indication
5) By End User: Hospitals, Diagnostic Labs, Academic and Research Institutions, Others End Users
Subsegments:
1) By Complete Blood Count (CBC): Hemoglobin Testing, Hematocrit Measurement, White Blood Cell Count, Red Blood Cell Count, Platelet Count, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH)
2) By Flow Cytometry: Immunophenotyping, Cell Cycle Analysis, Apoptosis Detection, Minimal Residual Disease (MRD) Testing, DNA Content Analysis
3) By Molecular Testing: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Reverse Transcriptase-PCR (RT-PCR), Fluorescence In Situ Hybridization (FISH), Microarray Analysis
4) By Genetic Testing: Germline Mutation Testing, Somatic Mutation Testing, Cytogenetic Testing, Chromosomal Aberration Detection, Single Nucleotide Polymorphism (SNP) Analysis
5) By Others Test Type: Bone Marrow Biopsy, Immunohistochemistry (IHC), Enzyme Assays, Serum Protein Electrophoresis (SPEP), Imaging Tests
What Trends Are Influencing The Hematologic Malignancies Testing Market?
Major companies within the hematologic malignancies testing market are concentrating on developing innovative diagnostic techniques, such as rapid molecular profiling, to offer healthcare providers precise and timely diagnostic tools. These tools aim to improve the early detection, treatment planning, and monitoring of blood cancers. Rapid molecular profiling is a diagnostic method that scrutinizes a patient’s genetic makeup to pinpoint mutations and variations, thereby enabling faster and more personalized treatment decisions. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based comprehensive cancer center, launched PanHeme. This next-generation gene sequencing tool is designed to diagnose hematologic cancers, including leukemia, lymphoma, and multiple myeloma, with greater accuracy and speed. The test identifies mutations in hundreds of genes in under 72 hours, significantly enhancing the speed and precision of diagnosis and ultimately guiding more personalized treatment decisions for patients.
Which Players Are Present In The Hematologic Malignancies Testing Market Space?
Major companies operating in the hematologic malignancies testing market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Sysmex Corporation, QIAGEN N.V., PerkinElmer Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., ArcherDx Inc., Guardant Health Inc., Sophia Genetics SA, Natera Inc., Roche Diagnostics International AG, Laboratory Corporation of America Holdings
Get The Full Hematologic Malignancies Testing Market Report:
Where Is The Hematologic Malignancies Testing Market Most Concentrated Geographically?
North America was the largest region in the hematologic malignancies testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Hematologic Malignancies Testing Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Hematologic Malignancies Testing Market 2026, By The Business Research Company
Hematology Diagnostic Devices And Equipment Market Report 2026
Dermatological Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatological-drugs-global-market-report
Hematocrit Test Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/hematocrit-test-devices-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
